ClinicalTrials.gg
CompletedNCT00770640PIOrenUpdated Sep 1, 2010

Efficacy of Pioglitazone and Insulin in Treating Subjects With Type 2 Diabetes Mellitus and Renal Failure.

A Phase 2 interventional study of Pioglitazone and insulin and Insulin in Diabetes Mellitus, sponsored by Takeda. Completed at 9 sites in Germany. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2010-09-01.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's title name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Takeda · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
30 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 — 7 open to participants now, 8 under way, 1 of them phase 3. Pioglitazone · Diabetes Mellitus, Type 2.

Enrollment
94th of 122
40 · median 103
Started
2008
with 12 others
Phase 2
8 of 122
1 open now
Registered
50th of 122
by date
Lead sponsor
27 of 122
Takeda

Among the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, this one is the 94th largest by enrollment, is one of 13 that started in 2008, is one of 8 in phase 2, and was the 50th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About pioglitazone

Pioglitazone: first FDA approval 1999 (ACTOS), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 30 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to determine the metabolic and cardiovascular effects of pioglitazone, once daily (QD), and insulin combination therapy in subjects with Type 2 Diabetes and Renal Failure.

Read the detailed description

Patients with type 2 diabetes mellitus and clinically significant kidney disease presenting with contra-indications for metformin and sulfonylurea drugs are usually treated with insulin therapy only. While the prolonged pharmacokinetic insulin profile due to delayed renal insulin elimination already is a hurdle for a successful therapy, impaired kidney function results in increased oxidative stress and cardiovascular risk, especially in patients requiring dialysis. Several potential mechanisms may explain this increased cardiovascular risk, and one, frequent finding is coexistence of several other independent cardiovascular risk factors including dyslipidemia, hypertension and smoking. In addition, impaired kidney function is associated with elevated markers of inflammation and other putative risk factors for cardiovascular events.

The focus of this study is to investigate whether pioglitazone may help improve overall metabolic and cardiovascular risks in patients with end stage renal disease, and if pioglitazone can potentially exert positive effects on kidney function in patients with renal failure requiring dialysis.

The duration of treatment for patients completing the study is approximately 26 weeks.

03

Conditions studied

  • Diabetes Mellitus

Keywords

  • Glucose Metabolism Disorder
  • Dysmetabolic Syndrome
  • Type II Diabetes
  • Diabetes Mellitus, Lipoatrophic
  • Dyslipidemia
  • Drug Therapy
04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 40 is below the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has Type 2 Diabetes Mellitus, and is a patient on insulin treatment for at least 3 months.
  • Has a less than 36 kg/m²
  • Has a glycosylated level greater than or equal to 6.0% and less than 10%.
  • Patient is on hemo-dialysis with or without residual excretion
  • An insulin dose greater than 20 IE/day

Exclusion criteria

Exclusion Criteria:

  • Has a history of type 1 diabetes.
  • Has acute infections.
  • History of to the study drugs or to drugs with similar chemical structures.
  • History of severe or multiple allergies.
  • Has a progressive fatal disease other than kidney failure.
  • Has a history of drug or alcohol abuse within the last 5 years.
  • A history of significant cardiovascular (e.g. Coronary heart failure based on stage III - IV), respiratory, gastrointestinal, hepatic (e.g. greater than 2.5 times the normal reference range) or hematological disease.
  • History of primary hyperaldosteronism
  • Acute myocardial infarction, open heart surgery or cerebral event (stroke/) within the last year prior to study start.
  • Any further antidiabetic treatment except pioglitazone and insulin.
  • History of macular edema.
  • Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:

    • Treatment with any other drug within 3 months before trial entry.
    • Treatment with within 3 months before trial entry.
    • Treatment with thiazolidinediones within the past 3 months.
    • If statin therapy applicable: Change of medication within the last 4 weeks.
    • Pre-treatment with gemfibrozil within the last 12 weeks.
    • Pre-treatment with rifampicin within the last 12 weeks.
  • Has uncontrolled unstable angina.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Pioglitazone 30mg QD

    (and variable insulin therapy)

    Drug: Pioglitazone and insulin

  • Placebo comparator
    Placebo QD

    (and variable insulin therapy)

    Drug: Insulin

Interventions

  • DrugPioglitazone and insulin

    Drug pages: Pioglitazone · Insulin

    Pioglitazone 30 mg, tablets, orally, once daily and variable insulin therapy for up to 24 weeks.

    Also known as: ACTOS®, AD-4833

  • DrugInsulin

    Pioglitazone placebo-matching tablets, orally, once daily and variable insulin therapy for up to 24 weeks.

07

What researchers measure

Primary outcomes

  1. Change of total daily Insulin Dose.

    Time frame: Week 24 or Final Visit.

Secondary outcomes

  1. Individual insulin doses to assess the number of patients with insulin reduction of greater than or equal to 30%.

    Time frame: Weeks 12 and 24 or Final Visit.

  2. Change from Baseline in Glycosylated Hemoglobin.

    Time frame: Weeks 12 and 24 or Final Visit.

  3. Change from Baseline in Glucose.

    Time frame: Weeks 12 and 24 or Final Visit.

  4. Change from Baseline in Insulin.

    Time frame: Weeks 12 and 24 or Final Visit.

  5. Change from Baseline in C-peptide.

    Time frame: Weeks 12 and 24 or Final Visit.

  6. Change from Baseline in Intact Proinsulin.

    Time frame: Weeks 12 and 24 or Final Visit.

  7. Change from Baseline in Adiponectin.

    Time frame: Weeks 12 and 24 or Final Visit.

  8. Change from Baseline in Angiotensin.

    Time frame: Weeks 12 and 24 or Final Visit.

  9. Change from Baseline in Relaxin.

    Time frame: Weeks 12 and 24 or Final Visit.

  10. Change from Baseline in fetuin A.

    Time frame: Weeks 12 and 24 or Final Visit.

  11. Change from Baseline in Carbonyl Protein.

    Time frame: Weeks 12 and 24 or Final Visit.

  12. Change from Baseline in Myeloperoxidase.

    Time frame: Weeks 12 and 24 or Final Visit.

  13. Change from Baseline in Matrix-Gla Protein.

    Time frame: Weeks 12 and 24 or Final Visit.

  14. Change from Baseline in High Sensitivity C-reactive Protein.

    Time frame: Weeks 12 and 24 or Final Visit.

  15. Change from Baseline in Cholesterol.

    Time frame: Weeks 12 and 24 or Final Visit.

  16. Change from Baseline in High-Density Lipoprotein.

    Time frame: Weeks 12 and 24 or Final Visit.

  17. Change from Baseline in Low-Density Lipoprotein.

    Time frame: Weeks 12 and 24 or Final Visit.

  18. Change from Baseline in Oxidized Low-Density Lipoprotein.

    Time frame: Weeks 12 and 24 or Final Visit.

  19. Change from Baseline in Triglycerides.

    Time frame: Weeks 12 and 24 or Final Visit.

  20. Change from Baseline in Matrix Metalloproteinase -9.

    Time frame: Weeks 12 and 24 or Final Visit.

  21. Change from Baseline in Monocyte Chemoattractant Protein -1.

    Time frame: Weeks 12 and 24 or Final Visit.

  22. Change from Baseline in E-selectin.

    Time frame: Weeks 12 and 24 or Final Visit.

  23. Pioglitazone in serum.

    Time frame: Week 12.

  24. Change from Baseline in intact Parathyroid Hormone.

    Time frame: Weeks 12 and 24 or Final Visit.

08

Study locations

9 sites
  • Schwetzingen, Baden-Württemberg, Germany
  • Wiesbaden, Hessen, Germany
  • Bottrop, Nordrhein-Westfalen, Germany
  • Düsseldorf, Nordrhein-Westfalen, Germany
  • Lüdenscheid, Nordrhein-Westfalen, Germany
  • Solingen, Nordrhein-Westfalen, Germany
  • Alzey, Rheinland-Pfalz, Germany
  • Ingelheim, Rheinland-Pfalz, Germany
  • Mainz, Rheinland-Pfalz, Germany
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2008
First posted
Oct 10, 2008
Start
Aug 2008
Primary completionActual
Jun 2010
CompletionActual
Jun 2010
Last update
Sep 1, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00770640
Lead sponsor
Takeda
First posted
Oct 10, 2008
Start date
Aug 2008
Primary completion
Jun 2010
Completion
Jun 2010
Last update
Sep 1, 2010

Study contacts

Medical Director
study director · Takeda Pharma GmbH, Aachen (Germany)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pioglitazone · Insulin

Start the discussion